Trial To Test Lynparza-Zytiga Combo Recruiting Men with Metastatic Castration-resistant Prostate Cancer

Trial To Test Lynparza-Zytiga Combo Recruiting Men with Metastatic Castration-resistant Prostate Cancer
A Phase 3 trial is recruiting men to test a combination of Lynparza (olaparib) and Zytiga (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Named PROpel (NCT03732820), the trial was recently presented at the 2019 Genitourinary Cancers Symposium, in San Francisco, in a poster titled "PROPEL: A randomized, phase III trial evaluating the efficacy and
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *